HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a price target of $10.
July 16, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Regulus Therapeutics and maintained a price target of $10.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100